Francis Arena, MD
Hematology & Oncology · Lake Success, NYNPI 1699760132
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $777,125 of the $1,004,736 with a category attached, or 77.3%. It is spread thinly across 49 manufacturers, the largest accounting for just 15.1%. Reporting peaked in 2023 at $266,496 and has fallen 76.8% since, to $61,802 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 896 payments — averaging $1121.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$152K
- Daiichi Sankyo Inc.$131K
- AstraZeneca$101K
- Incyte Corporation$87K
- Amgen$74K
- Regeneron Healthcare Solutions, Inc.$65K
- plus $395K from 43 others
Across 18 payments — averaging $9199.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$56K
- Novocure Israel Ltd$56K
- Halozyme Inc$30K
- Eli Lilly$23K
- Puma Biotechnology, Inc.$750
What the payments were for
- Consulting fees$75,9278%
- Speaking & faculty fees$777,12577%
- Travel & lodging$124,02012%
- Food & beverage$25,4363%
- Education$5130%
- Other$1,7140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,004,736 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 70 | $1,437 |
| Dexamethasone | 15 | $373 |
| Hydroxyurea | 18 | $345 |
| Allopurinol | 12 | $151 |
| Letrozole | 12 | $135 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lake Success
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.